Comparative Secretome Profiling and Mutant Protein Identification in Metastatic Prostate Cancer Cells by Quantitative Mass Spectrometry-based Proteomics

Overview

Journal Cancer Genomics Proteomics

Specialties Biochemistry
Genetics
Oncology

Date 2018 Jul 7

PMID 29976633

Citations 7

Authors

Oh Kwang Kwon

Ju Mi Jeon

Eunji Sung

Ann-Yea Na

Sun Joo Kim

Sangkyu Lee

Affiliations

Soon will be listed here.

Abstract

Background: Secreted proteins play an important role in promoting cancer (PCa) cell migration and invasion. Proteogenomics helps elucidate the mechanism of diseases, discover therapeutic targets, and generate biomarkers for diagnosis through protein variations.

Materials And Methods: We carried out mass a spectrometry-based proteomic analysis of the conditioned media (CM) from two human prostate cancer cell lines, belonging to different metastatic sites, to identify potential metastatic and/or aggressive factors.

Results: We identified a total of 598 proteins, among which 561 were quantified based on proteomic analysis. Among the quantified proteins, 128 were up-regulated and 83 were down-regulated in DU145/PC3 cells. Six mutant peptides were identified in the CM of prostate cancer cell lines using proteogenomics approach.

Conclusion: This is the first proteogenomics study in PCa aiming at exploring a new type of metastatic factor, which are mutant peptides, predicting a novel biomarker of metastatic PCa for diagnosis, prognosis and drug targeting.

Citing Articles

Liquid biopsy to personalize treatment for metastatic prostate cancer.

Lopez-Valcarcel M, Lopez-Campos F, Zafra J, Cienfuegos I, Ferri M, Barrado M Am J Transl Res. 2024; 16(5):1531-1549.

PMID: 38883349 PMC: 11170619. DOI: 10.62347/DICU9510.

Effect of the roasting levels of L. extracts on their potential antioxidant capacity and antiproliferative activity in human prostate cancer cells.

de Souza L, Carrero Horta I, de Souza Rosa L, Barbosa Lima L, Santos da Rosa J, Montenegro J RSC Adv. 2022; 10(50):30115-30126.

PMID: 35518253 PMC: 9056273. DOI: 10.1039/d0ra01179g.

Application of Proteogenomics to Urine Analysis towards the Identification of Novel Biomarkers of Prostate Cancer: An Exploratory Study.

Lima T, Barros A, Trindade F, Ferreira R, Leite-Moreira A, Barros-Silva D Cancers (Basel). 2022; 14(8).

PMID: 35454907 PMC: 9031064. DOI: 10.3390/cancers14082001.

Metastatic Prostate Cancer Cells Secrete Methylglyoxal-Derived MG-H1 to Reprogram Human Osteoblasts into a Dedifferentiated, Malignant-like Phenotype: A Possible Novel Player in Prostate Cancer Bone Metastases.

Antognelli C, Marinucci L, Frosini R, Macchioni L, Talesa V Int J Mol Sci. 2021; 22(19).

PMID: 34638532 PMC: 8508123. DOI: 10.3390/ijms221910191.

Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management.

Tonry C, Finn S, Armstrong J, Pennington S Clin Proteomics. 2020; 17(1):41.

PMID: 33292167 PMC: 7678104. DOI: 10.1186/s12014-020-09305-7.

References

Huang P, Lee C, Chin-Ming Tan B, Yeh Y, Chu L, Chen T . CMPD: cancer mutant proteome database. Nucleic Acids Res. 2014; 43(Database issue):D849-55. PMC: 4383976. DOI: 10.1093/nar/gku1182. View

Sheynkman G, Shortreed M, Cesnik A, Smith L . Proteogenomics: Integrating Next-Generation Sequencing and Mass Spectrometry to Characterize Human Proteomic Variation. Annu Rev Anal Chem (Palo Alto Calif). 2016; 9(1):521-45. PMC: 4991544. DOI: 10.1146/annurev-anchem-071015-041722. View

Alfaro J, Sinha A, Kislinger T, Boutros P . Onco-proteogenomics: cancer proteomics joins forces with genomics. Nat Methods. 2014; 11(11):1107-13. DOI: 10.1038/nmeth.3138. View

Zhang Y, Xi S, Chen J, Zhou D, Gao H, Zhou Z . Overexpression of LAMC1 predicts poor prognosis and enhances tumor cell invasion and migration in hepatocellular carcinoma. J Cancer. 2017; 8(15):2992-3000. PMC: 5604451. DOI: 10.7150/jca.21038. View

Eeles R, Goh C, Castro E, Bancroft E, Guy M, Olama A . The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol. 2013; 11(1):18-31. DOI: 10.1038/nrurol.2013.266. View

Quarta S, Vidalino L, Turato C, Ruvoletto M, Calabrese F, Valente M . SERPINB3 induces epithelial-mesenchymal transition. J Pathol. 2010; 221(3):343-56. DOI: 10.1002/path.2708. View

. UniProt: the universal protein knowledgebase. Nucleic Acids Res. 2016; 45(D1):D158-D169. PMC: 5210571. DOI: 10.1093/nar/gkw1099. View

Rauniyar N, Yates 3rd J . Isobaric labeling-based relative quantification in shotgun proteomics. J Proteome Res. 2014; 13(12):5293-309. PMC: 4261935. DOI: 10.1021/pr500880b. View

Mathivanan S, Ji H, Tauro B, Chen Y, Simpson R . Identifying mutated proteins secreted by colon cancer cell lines using mass spectrometry. J Proteomics. 2012; 76 Spec No.:141-9. DOI: 10.1016/j.jprot.2012.06.031. View

10.

Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J . STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2014; 43(Database issue):D447-52. PMC: 4383874. DOI: 10.1093/nar/gku1003. View

11.

Guo J, Yang J, Zhang X, Feng X, Zhang H, Chen L . A Panel of Biomarkers for Diagnosis of Prostate Cancer Using Urine Samples. Anticancer Res. 2018; 38(3):1471-1477. DOI: 10.21873/anticanres.12373. View

12.

Tanase C, Codrici E, Popescu I, Mihai S, Enciu A, Necula L . Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery. Oncotarget. 2017; 8(11):18497-18512. PMC: 5392345. DOI: 10.18632/oncotarget.14501. View

13.

Yang X, Lazar I . XMAn: a Homo sapiens mutated-peptide database for the MS analysis of cancerous cell states. J Proteome Res. 2014; 13(12):5486-95. DOI: 10.1021/pr5004467. View

14.

Ruggles K, Krug K, Wang X, Clauser K, Wang J, Payne S . Methods, Tools and Current Perspectives in Proteogenomics. Mol Cell Proteomics. 2017; 16(6):959-981. PMC: 5461547. DOI: 10.1074/mcp.MR117.000024. View

15.

Carreno B, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti A . Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015; 348(6236):803-8. PMC: 4549796. DOI: 10.1126/science.aaa3828. View

16.

Freed-Pastor W, Prives C . Mutant p53: one name, many proteins. Genes Dev. 2012; 26(12):1268-86. PMC: 3387655. DOI: 10.1101/gad.190678.112. View

17.

Hanash S, Pitteri S, Faca V . Mining the plasma proteome for cancer biomarkers. Nature. 2008; 452(7187):571-9. DOI: 10.1038/nature06916. View

18.

Beebe-Dimmer J, Hathcock M, Yee C, Okoth L, Ewing C, Isaacs W . The HOXB13 G84E Mutation Is Associated with an Increased Risk for Prostate Cancer and Other Malignancies. Cancer Epidemiol Biomarkers Prev. 2015; 24(9):1366-72. PMC: 4560608. DOI: 10.1158/1055-9965.EPI-15-0247. View

19.

Bush W, Moore J . Chapter 11: Genome-wide association studies. PLoS Comput Biol. 2013; 8(12):e1002822. PMC: 3531285. DOI: 10.1371/journal.pcbi.1002822. View

20.

Zhang M, Wang B, Xu J, Wang X, Xie L, Zhang B . CanProVar 2.0: An Updated Database of Human Cancer Proteome Variation. J Proteome Res. 2016; 16(2):421-432. PMC: 5515284. DOI: 10.1021/acs.jproteome.6b00505. View